Let’s play a little game. Let’s say that you’re the CSO at a cancer pharma company, and you have to choose a target to go after. Here’s a gene – high expression is associated with poor prognosis in brain cancer. Looks like a good candidate for an inhibitor right?

Today in Science Magazine, together with my former colleagues at NIBR, we report the discovery and characterization of first molecular glue degraders of the WIZ transcription factor (TF) for fetal hemoglobin derepression and therapeutic consideration in Sickle Cell Disease. 1/10

#TiNivo2 results are out —adding PD1 inhibitor nivolumab simply does not help after rechallenge /progression on prior immunotherapy. Time to follow level 1 evidence! PRNEWS Targeted Oncology OncLive.com KidneyCAN Kidney Cancer Uromigos Oncology Brothers —implications beyond renal cancer ?

T-DXd is approved for patients with any HER2+ solid tumor (IHC 3+ on tissue) Could ctDNA also allow to identify pts benefiting from T-DXd? In the HERALD trial, 62 pts with 16 cancer types having ctDNA-detected HER2 amplifications received T-DXd ORR 56% ascopubs.org/doi/10.1200/JC…

New patent from Arvinas CEREBLON-BASED KRAS DEGRADING PROTACS 🔥🔥🔥

Results from DESTINY-CRC02 published in The Lancet Oncology. Among patients with pretreated, HER2+ mCRC, the lower dose of T-DXd (5.4 mg/kg) led to higher ORR and longer PFS than the higher dose (6.4 mg/kg), with nearly half the rate of ILD. Less can be more. thelancet.com/journals/lanon…

1/ For the Atlantic's September cover story, I took 3 trips to the Darien Gap to try to understand the forces driving people there: instability, policy failures, and smuggling orgs that are eager to take advantage. lynsey addario captured it all. theatlantic.com/magazine/archi…

Another week, another tumor board where I referenced this brilliant Krishan Jethwa flowchart to guide multidisciplinary discussion of rectal cancer management #crcsm

Esmo presidential sessions ESMO - Eur. Oncology #ESMO24 What is the exciting data to look forward to - My Take 1 - OS data for Keynote- 522 - pembrolizumab for Neoadjuvant TNBC. 2- NIAGARA - neoadjuvant Durvalumab plus chemo followed by sx and adjuvant Durvalumab for MIBC . 3 - OS data

Recently published: ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors, by Christopher T. Chen et al. bit.ly/3Mq8XjY Chris Chen, MD Vishesh Khanna MD Naoto T Ueno, MD, PhD @alexspiramdphd #openaccess

Excited to share our Journal of Clinical Oncology paper with Dan Petrylak ylt Scott Tagawa Neeraj Agarwal, MD, FASCO Cora Sternberg 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Rohit Jain, MD et al. on SG alone s/p ICI: ORR 32%, mDOR 6 months, rapid responses, should give G-CSF as primary prophylaxis with SG in urothelial Ca! OncoAlert

My Top 10 Gastrointestinal Cancer Abstracts #ESMO24 ESMO - Eur. Oncology

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up! ESMO - Eur. Oncology Tom Powles Laurence Albiges Viktor Grünwald Ravindran Kanesvaran Rana McKay, MD, FASCO Giuseppe Procopio silke gillessen Cris Jeremy Teoh Guillermo de Velasco OncoAlert KidneyCAN Kidney Cancer

1/This great El País English Edition article explains one of the most exciting recent discoveries in the Gene & RNA editing field - the discovery of Patrick Hsu’s Bridge RNA - a new class of RNA guided systems which enables large scale gene editing even beyond RNA & DNA cuts. Here’s my🧵👇

Tivozanib +/- nivolumab in IO pretreated M1 renal cancer showed retreatment with IO makes absolutely no difference. This is on top of CONTACT3 which showed the same thing.We need to stop retreating with IO.These data apply in the post adjuvant setting too without data #ESMO2024

Presidential for silke gillessen Uromigos #ESMO2024 Radium223 + enza vs enza alone shows a PFS and OS advantage in metastatic CRPC. PEACE3 is an investigator trial and rejuvenates radium-223 in prostate cancer. 0.69 HR for PFS and OS !!!

Per Ignacio Garrido-Laguna RMC-6236, a RAS(ON) multiselective inhibitor, can induce responses across a variety of kras mutations even in heavily pretreated patients with pancreatic adenocarcinoma! #pancsm

Impressive data! Will be interesting to see whether adjuvant therapy can be reduced or eliminated for those patients who achieve a pCR to neoadj durva + chemo. Perhaps ctDNA can help guide this.

⭐️OUTSTANDING balanced discussion of Niagara study by global thought leader Petros Grivas . Very thoughtful discussant points. Immediately becomes new standard of care but there are still some unanswered questions for clinical practice. Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Toni Choueiri, MD

I found these three summary slides from Channing Der on (left) diverse mechanisms of action for KRAS inhibitors & (center, right) acquired genetic mechanisms of resistance to KRASi really useful. #AACRPan24